

PAUL JAI SEKHRI

130 West 19th Street
Townhouse E
New York, NY 10011
+1 917 660 4044
psekhri@me.com

Summary 30+ years of deep operational experience in life sciences including general management, corporate and business strategy, technology identification and drug development, business development, M&A, financial strategy, product development, and commercial strategy (including sales and marketing strategy). In-depth knowledge of multinational pharmaceutical and biotechnology markets and products. Skilled at creating and executing corporate strategy. Strong international experience. Proven leadership, entrepreneurial, and organizational skills in both small biopharmaceutical, large and small pharmaceutical companies, and venture capital/private equity firms. Comprehensive board experience having served as either a Director or Chairman on more than 25 Boards of Directors.

Experience eGenesis, Inc. Cambridge, MA, New York, NY

President and CEO (January 2019 – Present)

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.

Highline Therapeutics/Versant Ventures

New York City, NY

Operating Partner (October 2016 – May 2018)

Working with Versant Ventures and their New York-based innovation accelerator Highline Therapeutics, part-time (~10%), in helping them identify new technologies in order to create innovative biotech companies. Focused on company formation, strategy, financing, hiring, and partnering. In 2016 completed a “build-to-buy” transaction between Anokion and Celgene; assisted in licensing key technology from Memorial Sloan Kettering for Bluerock, a Newco created with Versant and Bayer.

Lycera Corporation

Ann Arbor, MI, Philadelphia PA, New York, NY

President and CEO (February 2015 – January 2019)

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells. Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients. With senior leadership and a team of scientists who represent the best of their fields, Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world.

In first first four months at the company, successfully negotiated and closed a transformational deal for Lycera with Celgene, raising over 100M of non-dilutive capital to move all of the company’s innovative programs

forward. Retained key personnel and filled out the executive team with a world-class Chief Medical Officer as well as Chief Financial Officer.

Sanofi S.A.

Bridgewater, NJ and Paris, France

**Senior Vice President, Integrated Care, Global Center of Excellence (April 2014 – January 2015)
Member, Global Leadership Team**

Responsible for creating new global unit focused on healthcare solutions, “beyond the pill” including improving patient outcomes, drug/device combinations, digital health solutions, and focused equity investments in external companies. Established ongoing collaboration with Google Health (now Verily) around a “smart” contact lens able to detect glucose in tears.

Teva Pharmaceuticals, Ltd.

Tel Aviv, Israel

Group Executive Vice President, Global BD and Chief Strategy Officer (June 2013 – March 2014)

Reporting to the CEO, responsible for Global Business Development (both Specialty, Generics, and OTC), Search and Evaluation, Alliance Management, Strategic Planning, Strategic Initiatives, Mergers and Acquisitions - all Corporate Development activities for a global pharmaceutical company. Member of the Teva Executive Committee, Chairman of the Transactions sub-committee, Member of the Investor Relations sub-committee. Oversee a global department of more than 100 employees. Executed two M&A deals (the acquisition of Microdose and Labrys) and three different licensing deals. Reorganised and streamlined the department to meet the needs of the corporate strategy.

TPG Biotech (wholly-owned venture affiliate of TPG Capital)

New York City, NY

Operating Partner (2009 - 2013)

Operating Partner whose goal is to ensure the health and success of the 52 companies within the TPG Biotech portfolio. Responsible for aiding our companies with corporate and business development, strategy, and all human capital issues. Develop and maintain key senior management relationships within large pharmaceutical and biotech companies. Board Positions: Patient Safe Solutions, MacroGenics, Moksha8 (Chairman), IMS Health (Observer), Tandem Diabetes.

Cerimon Pharmaceuticals, Inc.

South San Francisco, CA

Founder, President and Chief Executive Officer, Inc. (2005 - 2008)

Founded a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation associated with autoimmune diseases, and pain management. Licensed in four late-stage assets from Novartis and a Japanese partner. Secured \$70 million Series A financing in late 2005 with premier investors including MPM, Nomura Phase4 Ventures, and OrbiMed Advisors. The company filed three successful IND's and built a world-class team of 27 professionals.

ARIAD Pharmaceuticals, Inc.

Cambridge, MA

President and Chief Business Officer (2003 - 2004)

As an Officer of this \$600 M market capitalization publicly traded company (NASDAQ: ARIA), responsible for general management and all business development/commercial activities. Since joining the company, contributed to raising a total of \$80 M, negotiated three deals with stent companies for the companies lead drug product (drug-eluting stents); arranged for clinical and commercial supply of drug product from external manufacturers; created the Phase II clinical plan for the company's lead compound; initiated partnering

negotiations with 4/5 of the top global pharmaceutical companies. Present regularly to investors, analysts, and the media.

The Sprout Group, (now, New Leaf Ventures)

New York, NY

Partner (2003)

Responsible for identification, due diligence, and transactions for healthcare technology companies. Worked closely on three recently executed deals (Nycomed, Cellgate, Corixa) with an overall investment of ~100 M USD.

Novartis Pharma AG

Basel, Switzerland and East Hanover, NJ

Senior Vice President and Head, Global Search and Evaluation, M&A (2001 - 2003)

Responsible for the identification and evaluation of compound in-license opportunities, platform technology, and corporate acquisition activities on a worldwide basis. Building from the development and implementation of the Novartis Pharma Disease Area Strategy, this new group has been created to ensure Novartis' competitive access to a constant flow of new and innovative compounds.

Identified, evaluated and executed four deals within 8 months: Dainippon (early stage preclinical), Torrent Pharmaceuticals (early stage preclinical), Regeneron (late stage preclinical/IL1 TRAP), Idenix (late stage compound licensing, and 57% acquisition).

Member of the top senior management decision-making boards at Novartis Pharma including: Innovation Management Board, Deal Review Committee, Research Management Board.

Vice President and Head, Global Early Commercial Development (1999 - 2001)

Global responsibility for the development and commercialisation of new drugs emerging from Research at Novartis Pharma. Defined and established a new department within Novartis Pharma, the objective to develop and provide Research and Development with value-added clinical and commercial direction necessary to optimise clinical value and commercial opportunity. Other responsibilities include close affiliation with Business Development and licensing BD&L to assess and value potential in-licensed compounds. Creation of market-driven competitive strategy; ultimately creating and refining a therapeutic product profile (TPP) with a clearly defined differential competitive advantage.

Defined and established the Early Commercial Development Group and staffed 20 senior positions

Developed key interfaces with Research and Development (PRIDEs) to provide value-added development, clinical, and commercial input into these functions; created a novel marketability process to score early compounds based upon their commercial viability

Created a unified approach to Therapeutic Area strategy across all Novartis' Therapeutic Areas

Northeast Consulting Resources, Inc. (1997 - 1999)

Boston, MA

focused on pharma and biotech markets

Partner

Strategic management consulting firm specialising in mapping the emerging future through proprietary scenario planning, particularly the interplay between business strategy and information technology. Focus on Fortune 50 pharmaceutical companies, biotechnology (especially genomics and bioinformatics companies) and medical-device companies in developing corporate and business strategy. Help start-up and mid-size organisations move new technology through full commercialisation as well as identify and cultivate potential alliance partners.

Aligned the IT resource requirements with the business needs for the Research Division of a top three pharmaceutical company

Created a successful market penetration strategy for a newly created division of a Fortune 100 pharmaceutical supply company

Generated over \$600,000 in US revenue in first six months with newly signed life science clients

Presented the firm's qualifications through presentations to senior management in 9 of the top 10 global biopharmaceutical companies

Responsible for expanding the firms' business into Europe resulting in a 500% increase in revenues (to \$3 million) in the first year

Millipore Corporation (1995 - 1997)

Bedford, MA

devices for purification and analysis

Director/General Manager, Applied Microbiology Strategic Business Unit

Based in Paris, France, managed and led a \$75 million global business unit delivering Quality Assurance products and services to the biotechnology, medical device, and pharmaceutical industries. Directed business development and determined overall business strategy. Identified, analysed, and selected partners for corporate joint ventures and acquisitions.

Increased Division revenue growth to 16% from 3% while increasing margins 5 percentage points

Identified, structured, negotiated and closed two corporate joint ventures with biotechnology companies. Forecasted potential revenues, developed earnings models, created proforma P&L's, and presented acquisition candidates to Board of Directors

Analysed and developed strategic collaborations with two Fortune 500 pharmaceutical companies

PerSeptive Biosystems, Inc. (1993 -1995)

Cambridge, MA

products for bioseparations and diagnostics

**Director/General Manager, MicroAnalytical Business Unit and
Corporate Director Marketing/Business Development**

Managed a \$20MM business unit and company-wide business development activities, including structuring strategic alliances and collaborations with major biopharmaceutical and medical device companies and bringing new technologies to market. Directed sales and marketing of bioseparation and analytical products to biotechnology and pharmaceutical companies worldwide.

Negotiated, analysed and implemented twelve collaborations with leading global pharmaceutical companies for PerSeptive's immunoassay-based technologies

Contributed to corporate secondary offering package raising \$58 million for the company. Conducted financial modelling and corporate valuations of potential acquisition targets

Millipore Corporation (1990-1993)

Bedford, MA

Senior Manager, Biotechnology Market Development

Explored and championed new technologies for development and identified potential corporate acquisitions. Directed marketing of bioprocess products to the pharmaceutical industry.

Product Manager and European Liaison

Commercialised a new membrane-based system (Viresolve™) for virus filtration. Coordinated all aspects of product development: research and engineering, manufacturing, pricing, market development, global regulatory interaction, marketing communication, sales force education, and world-wide applications support.

Directed over 100 feasibility trials and evaluations world-wide with major biopharmaceutical companies

Recognised in a Harvard Business School case study, used in the MBA curriculum, detailing Viresolve's (viral removal technology for biotherapeutics) introduction as an example of successful product commercialisation

Zymark Corporation (1989 -1990)

Hopkinton, MA

pharmaceutical and biotechnology automation and robotics

Director of Marketing

Directed business strategy for company providing laboratory robotics and automated applications for the clinical marketplace, primarily within the pharmaceutical, forensic, and biotechnology industries. Participated in new product development, design and evaluation.

Secured \$3.5 million development contract with the leading global company in clinical and diagnostic testing.

Genex Corporation (1988 -1989)

Gaithersburg, MD

leader in biotech diagnostics, therapeutics

Marketing Manager

Managed numerous biotechnology product introductions. Developed strategic partnerships and R&D alliances.

Negotiated multi-million dollar contract with Maryland Medical Laboratories for an affinity protein medical device

Secured a major contract with a diagnostic company to incorporate new compounds into a cancer diagnostic kit

Education

University of Maryland School of Medicine

Baltimore, MD

Postgraduate study, Clinical Anatomy and Neuroscience, 1986

Completed first and second-year medical school curriculum: Anatomy, Biochemistry, Embryology (honors), Genetics, Hematology, Histology, Immunology, Microbiology, Neuroscience, Pharmaceutical Biochemistry, Pathology, Physiology, Psychiatry, and Virology.

University of Maryland

College Park, MD

Postgraduate study, Membrane Physiology, 1983

B.Sc., Zoology, 1981

Languages

English (native), French (fluent)

Directorships For-Profit

Ipsen S.A., Director (June 2018 – Present)

Compugen Ltd., Chairman of the Board (October 2017 – Present)

Alpine Immune Sciences, Inc., Director, (2017 – Present)

Topas Therapeutics, GmbH, Chairman of the Board of Supervisory Directors (2017 – 2019)

Petra Pharma Corporation, Chairman of the Board (2016 – Present)

Nivalis Therapeutics, Director (2016 - 2017)

Pharming N.V., Chairman of the Board of Supervisory Directors (2015 – Present)

Lycera Corporation, Director, President and CEO (2015 – 2019)

Enumeral Holdings, Director (2014- 2017)

Veeva Systems, Director (2014 – Present)

Ascendancy Healthcare, Director (2011 – 2015)

Macrogenics, Inc., Director (2010 – 2013)

Moksha8, Director and Chairman of the Board (2011 – 2013)

IMS Health, Board Observer (2010 – 2013)

PatientSafe Solutions, Inc., Director (2011- Present)

Tandem Diabetes, Director (2011 – 2013)

Kai Pharmaceuticals, Inc., Director (2007 - sold to Amgen July 2012)

Intercept Pharmaceuticals, Inc., Director (2007 – 2012)

APT Pharmaceuticals, Director (2006 – 2009)

ARYx Therapeutics, Director, (2004 – 2008)

Biodel, Director, (2005 – 2008)

CITA Neuropharmaceuticals, Director (2004 – 2006)
Cerimon Pharmaceuticals, Founder, President, CEO, Director (2004 – 2009)

Non-Profit

The Metropolitan Opera, Trustee (2018 – Present)
The Orchestra of St. Lukes, Trustee (2018 – Present)
The Knights, Trustee (2017 – Present)
The English Concert in America, Trustee (2016 – 2019)
Caramoor Center for Music and the Arts, Trustee (2015 – 2018)
Young Concert Artists, Inc., Vice Chairman (2013 – 2018)
Carnegie Hall, Member of the Patrons Council and Founder, Life Sciences Council (2012 – Present)
The Cancer Research Institute, Director (2006 – 2016)
The TB Alliance, Director (2012 – 2018)
The Tectonic Theater Project, Director (2012 – 2016)
Carnegie Hall, Member of the Board of Trustees (2009-2012)
The Decoda Ensemble, Trustee (2019-Present)

Affiliations

Target PharmaSolutions, Inc., Advisor (2018 - 2019)
Trialspark, Advisor to CEO (2017-Present)
Capsule, Advisor to CEO (2017 – 2018)
Nuvelution Pharma, Advisor to CEO (2016 – Present)
Welkin Health, Advisor to CEO (2016 - 2019)
Benchling, Advisor to CEO (2017 – Present)
iCardiac, Advisor to CEO (2015 – 2017)
BioExec Institute, Board of Directors (2008 – Present)
Ylida Novik Concerto Competition, Bi-Annual Sole Sponsor (2012 – Present)